Question for written answer E-002357/2022
to the Commission
Rule 138
Maria Arena (S&D), **Eric Andrieu** (S&D), **Marie Toussaint** (Verts/ALE), **Martin Hojsík** (Renew), **Jutta Paulus** (Verts/ALE), **Cindy Franssen** (PPE), **Frédérique Ries** (Renew)

Subject: Clarifications on the uptake of NAMs in the context of the update of REACH information requirements

The Commission is currently reviewing the information requirements (IRs) in the Registration, Evaluation, Authorisation and Restriction of Chemicals Regulation (REACH) in order to close information gaps on important hazards and better integrate new approach methodologies (NAMs). NAMs are at an early stage of development and it will be a long time before they are fully ripe for regulatory use. This is especially the case for sensitive endpoints such as endocrine disruption. Moreover, hazard identification under the Classification, Labelling and Packaging Regulation (CLP) requires *in vivo* data. The progressive integration of NAMs under REACH IRs raises important questions about the regulatory compatibility of REACH and CLP.

Given this:

1. How will the Commission guarantee that integrating NAMs in REACH IRs promotes increased health and environmental protection?

2. Is the Commission ready to adapt the level of proof required for hazard identification in order to speed up NAM regulatory uptake, and if so, how is it planning to proceed?

3. How will the update of the IRs be addressed in the upcoming REACH impact assessment, how will this influence the timing of this impact assessment, and how is the Commission planning to ensure coherence between the general update of the REACH IR and the parallel update specifically on endocrine disruptors?